Akums Drugs and Pharmaceuticals Ltd
Akums Drugs Reports Q2 FY27 Standalone Net Profit of Rs. 326.37 million
RESULTS
● No Immediate Change
MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 05:17 PM IST · BSE ID: d17df2a4-550c-4336-ba68-c0bf57dbf1b0
View Original BSE Filing (PDF)
💡
In Simple Terms
Akums Drugs approved its latest quarterly financial results, showing revenues of over Rs. 3,950 million and a profit of Rs. 326 million.
🤖 AI Summary
- Board approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026 (Q2 FY27).
- Standalone revenue from operations for Q2 FY27 was Rs. 3,950.47 million, while total income stood at Rs. 4,208.44 million.
- Standalone net profit for Q2 FY27 reported at Rs. 326.37 million, with basic and diluted EPS of Rs. 2.13.
- Mr. Sanjay Kumar, President – Operations, has been designated as Senior Management Personnel (SMP).
- Company is no longer required to submit a Statement of Deviation for forthcoming quarters as 100% IPO proceeds are utilized.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Standalone) Q2 FY27
3,950.47 million
27.71%
Profit for the period (Standalone) Q2 FY27
326.37 million
38.68%
Basic and Diluted EPS (Standalone) Q2 FY27
2.13
39.22%
Total Income (Standalone) Q2 FY27
4,208.44 million
25.10%
Tax demand (earlier periods)
600.92 million
🏢 How This Affects the Company
The approval of financial results indicates the company's continued operational activity in the pharmaceutical sector. The full utilization of IPO proceeds suggests completion of previously planned projects or growth initiatives.
Akums Drugs reported a standalone total income of Rs. 4,208.44 million and a net profit of Rs. 326.37 million for Q2 FY27. This provides an update on the company's financial performance.
The designation of Mr. Sanjay Kumar as Senior Management Personnel strengthens the company's leadership structure in operations. Full utilization of IPO funds completes the financial deployment for capital projects or expansion.
The disclosure regarding a tax demand of Rs. 600.92 million for earlier periods, which management believes requires no adjustment, notes a specific financial contingency that is currently under appeal.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing and management designation.
👤
Who Is Affected
All shareholders are indirectly affected by the company's Q2 FY27 financial performance, including standalone net profit of Rs. 326.37 million and the ongoing tax demand of Rs. 600.92 million.
🔍
Management Signal
Management's decision to designate Mr. Sanjay Kumar as Senior Management Personnel indicates focus on operational leadership. The assertion that no adjustments are needed for the tax demand reflects their confidence in the appeal process.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — monitor revenue and profit trends.
Update on the Rs. 600.92 million tax demand appeal.
Any future Board announcements on management changes or strategic decisions.
MEDIUM RISK
The outstanding tax demand of Rs. 600.92 million introduces a financial contingency, despite management's view.
💡 Investor Takeaway
Akums Drugs and Pharmaceuticals Limited reported standalone revenue from operations of Rs. 3,950.47 million for Q2 FY27 and a net profit of Rs. 326.37 million. The company confirmed full utilization of IPO proceeds. A tax demand of Rs. 600.92 million is under appeal.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Revenue from Operations reached Rs. 3,950.47 million in Q2 FY27, showing growth from Rs. 3,093.15 million in Q2 FY26.
- The company's IPO proceeds are 100% utilized, removing the requirement for future deviation statements under Regulation 32(2) of SEBI LODR Regulations.
⚠️ Concerns
- Standalone Profit for the period in Q2 FY27 was Rs. 326.37 million, a decrease from Rs. 448.39 million in Q1 FY27 (quarter ended 30 June 2026).
- A tax demand of Rs. 600.92 million for the block period from 01 April 2018 to 12 March 2025 has been raised by Income-tax authorities, currently under appeal.
📅 Company Track Record
Akums Drugs and Pharmaceuticals Limited reported full year FY26 results in May 2026, with the Board approving a dividend of Rs. 3.00 per share. This current filing details Q2 FY27 performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Akums Drugs' standalone revenue and net profit for Q2 FY27?
Akums Drugs and Pharmaceuticals Limited reported standalone revenue from operations of Rs. 3,950.47 million and standalone net profit of Rs. 326.37 million for the quarter ended 30 September 2026.
What was the Basic and Diluted EPS for Akums Drugs in Q2 FY27?
The Basic and Diluted Earnings Per Share (EPS) for Akums Drugs and Pharmaceuticals Limited was Rs. 2.13 for the quarter ended 30 September 2026.
Has Akums Drugs fully utilized its IPO proceeds?
Yes, Akums Drugs and Pharmaceuticals Limited has fully utilized 100% of its Initial Public Offer (IPO) proceeds, removing the requirement to submit deviation statements for forthcoming quarters.
What management change was approved by the Board for Akums Drugs?
The Board of Directors of Akums Drugs and Pharmaceuticals Limited approved the designation of Mr. Sanjay Kumar, President – Operations, as Senior Management Personnel of the Company.
Is there any outstanding tax demand against Akums Drugs?
Yes, there is a tax demand of Rs. 600.92 million for the block period from 01 April 2018 to 12 March 2025, raised by Income-tax authorities, which the company has appealed.
Questions based on this BSE filing only. For information purposes.